Enovis (ENOV) director Christine Ortiz awarded 9,346 common shares in stock grant
Enovis (ENOV) director Christine Ortiz was granted 9,346 shares of common stock on May 19, 2026, as part of her compensation, with no purchase price. Following this transaction, Ortiz directly owns 25,011 common shares of Enovis. This stock grant is reported as a routine equity-based compensation and not an open-market purchase or sale.
Enovis (ENOV) director Liam Kelly receives grant of 9,346 common shares
Liam Kelly, a director at Enovis (ENOV), was granted 9,346 shares of common stock as compensation, meaning the shares were awarded at $0.00 per share. This transaction, reported via a Form 4 filing, increases his direct holdings to a total of 28,950 Enovis common shares. The filing indicates this was a grant and not an open-market purchase or sale.
Director Angela S. Lalor receives 9,346 Enovis (ENOV) shares as stock grant
Enovis director Angela S. Lalor was granted 9,346 shares of common stock on May 19, 2026, as compensation. The shares were awarded at $0.00 per share, increasing her direct holdings to 31,486 Enovis common shares. This transaction was reported via a Form 4 filing and represents a stock grant rather than a market purchase.
Enovis (ENOV) director Shirley Brady receives 9,346-share stock grant, holds 110,589
Enovis director Shirley Brady received a grant of 9,346 shares of common stock on May 19, 2026, as compensation. This award, valued at $0.00 per share, increased her direct holdings to 110,589 Enovis common shares. The transaction, reported in a Form 4 filing, is a routine equity grant for board compensation and not an open-market purchase or sale.
What's Driving the Recent Buzz Around Enovis (ENOV) Stock
Enovis (ENOV) has garnered investor attention due to recent open-market stock purchases by its Chief Administrative Officer, Oliver Engert, despite the stock's underperformance. This insider confidence aligns with analysts' "Moderate Buy" rating, who see significant upside potential despite the company's mixed Q4 CY2025 results and past goodwill impairments. The medical technology company's strategic focus on orthopedic innovation and global expansion positions it for a potential long-term rebound, attracting investors with a higher risk tolerance and long-term view.
Enovis (NYSE: ENOV) investors back 2020 incentive plan share and pay changes
Enovis Corporation shareholders approved an amendment to the 2020 Omnibus Incentive Plan, authorizing an additional 3,650,000 shares for equity awards and increasing the annual compensation cap for Outside Directors from $350,000 to $750,000. All ten director nominees were elected, Ernst & Young LLP was ratified as the independent auditor, and executive officer compensation received advisory approval. These decisions were made at the Annual Meeting held on May 19, 2026, as reported in an 8-K filing.
Enovis shareholders approve amendment to 2020 incentive plan at annual meeting
Enovis Corporation shareholders approved an amendment to the company's 2020 Omnibus Incentive Plan, authorizing additional shares and increasing compensation limits for outside directors. This decision was made at their annual meeting, where they also re-elected directors, ratified their accounting firm, and approved executive compensation on an advisory basis. The amendment allows for 3,650,000 more shares of common stock for issuance and raises the maximum aggregate dollar value of equity-based awards and cash compensation for outside directors from $350,000 to $750,000 annually.
Is Enovis’ Improving Q1 2026 Results And Reaffirmed Outlook Altering The Investment Case For ENOV?
Enovis Corporation reported improving Q1 2026 results with reduced net loss and reaffirmed its 2026 revenue outlook of US$2.31 billion to US$2.37 billion. This indicates progress in operational performance and management confidence, despite historical losses and complexities from acquisitions. The article suggests these developments support the near-term catalyst of better execution, but investors should remain aware of ongoing integration challenges and potential delays.
Small-Cap Stock Picks: Hims & Hers Buy, Enovis & LifeStance Sell | May 2026 - News and Statistics
This article analyzes several small-cap stocks, recommending Hims & Hers Health as a buy while suggesting Enovis and LifeStance Health as sells for May 2026. Enovis shows declining sales and negative returns, while LifeStance Health is criticized for subscale operations and low free cash flow. Hims & Hers Health, with its telehealth platform, is identified as a promising investment opportunity.
Enovis (ENOV) CFO has 7,774 shares withheld to cover taxes
Enovis Corp's CFO, Phillip Ben Berry, had 7,774 shares withheld by the company at $25.99 each to cover tax obligations related to restricted stock units. This transaction was a tax withholding and not an open-market sale. After this, Berry directly holds 150,822 shares of Enovis common stock.
Enovis (ENOV) CEO McDonald has 12,634 shares withheld for RSU taxes
Enovis CEO Damien McDonald reported a tax-related disposition where 12,634 shares of common stock were withheld by the company to satisfy tax obligations related to net-settled restricted stock units. This transaction, which occurred on May 12, 2026, was not an open-market sale. After the withholding, McDonald directly holds 234,042 shares of Enovis common stock.
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
Wall Street analysts project a potential 65.45% upside for Enovis (ENOV), with an average price target of $43. Despite skepticism surrounding the reliability of price targets, analysts' increasing optimism regarding the company's earnings prospects and its Zacks Rank #2 (Buy) status suggest a potential for solid stock growth. Investors are advised to use price targets as a starting point for research rather than the sole basis for investment decisions.
Enovis (ENOV) Valuation Check After Reaffirmed 2026 Guidance And Solid First Quarter Results
Enovis (ENOV) has reaffirmed its 2026 revenue guidance and reported solid first-quarter results, including US$589.15m in sales. Despite a recent share price increase, the stock is considered significantly undervalued by Simply Wall St's analysis at around $25.70 per share, with a fair value estimate of $44.73, driven by anticipated growth in orthopedic care but facing integration and technology launch risks. Investors are encouraged to review the underlying data for a complete picture.
Enovis (ENOV) Valuation Check After Reaffirmed 2026 Guidance And Solid First Quarter Results
Enovis (ENOV) has reaffirmed its 2026 revenue guidance of US$2.31b to US$2.37b and reported solid first-quarter sales of US$589.15m, alongside a reduced net loss. Despite a recent 17.3% share price return over 90 days, the one-year total shareholder return has declined by 29.0%. Simply Wall St's analysis suggests Enovis is currently undervalued, with a fair value estimate of $44.73 compared to its current trading price of approximately $25.70, although integration issues and technology launch delays could pose hurdles.
Is There Now An Opportunity In Enovis (ENOV) After Multi Year Share Price Slump
Enovis (ENOV) stock has seen significant declines over the past few years but shows signs of being undervalued according to Simply Wall St's analysis. A Discounted Cash Flow (DCF) model suggests a 53.5% discount to its estimated intrinsic value, and its Price-to-Sales (P/S) ratio is well below industry averages. Investors might find an opportunity given these valuation metrics, despite the prolonged share price slump.
Is There Now An Opportunity In Enovis (ENOV) After Multi Year Share Price Slump
Enovis (ENOV) has experienced significant share price declines over multiple years, falling 32.2% in the last year and 67.3% over five years, despite recent minor gains. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 53.5%, with an intrinsic value of $53.31 per share. Additionally, Enovis's Price/Sales ratio of 0.63x is well below the industry average, further indicating it might be undervalued.
Enovis (ENOV) Is Up 16.3% After Reaffirming 2026 Outlook And Narrowing Losses – Has The Bull Case Changed?
Enovis Corporation (ENOV) reported Q1 2026 results with increased sales and a narrowed net loss, leading to a 16.3% stock price increase. The company reaffirmed its full-year 2026 revenue guidance, citing confidence in its Reconstructive segment and new technologies like Arvis, which supports its innovation-led growth narrative. This performance, despite ongoing losses, signals management's conviction in product launches and the potential for long-term profitability.
Enovis Q1 Earnings Call Highlights
Enovis (ENOV) reported a solid start to 2026, with an emphasis on share gains in reconstructive surgery, stable growth in prevention and recovery, and continued investment in new products like ARVIS and Nebula. The company delivered 3% organic revenue growth despite fewer selling days, with days-adjusted organic growth reaching 6%. Management reaffirmed its 2026 guidance, citing strong underlying procedure demand despite macro volatility and tariffs.
Enovis Corporation 2026 Q1 - Results - Earnings Call Presentation (NYSE:ENOV)
Enovis Corporation (NYSE: ENOV) has released its Q1 2026 earnings, reporting an EPS of $0.89, which beat estimates by $0.08, and revenue of $589.15 million, surpassing expectations by $16.71 million and representing a 5.43% year-over-year increase. This article presents the slide deck published by Enovis in conjunction with their earnings call.
Enovis (ENOV) Is Up 16.3% After Reaffirming 2026 Outlook And Narrowing Losses – Has The Bull Case Changed?
Enovis (ENOV) reported Q1 2026 results with increased sales and narrowed net losses, while reaffirming its full-year 2026 revenue guidance. The company’s innovation-led growth strategy, particularly in its Reconstructive segment and new technologies like Arvis, is central to its investment narrative. Despite ongoing macroeconomic uncertainties, management shows conviction in achieving its revenue targets, which analysts are closely watching against more optimistic forecasts for sustained profitability.
Enovis Q1 Earnings Call Highlights
Enovis (ENOV) reported a solid start to 2026, achieving 3% organic revenue growth in Q1, or 6% on a days-adjusted basis, driven by strong performance in its reconstructive surgery business, particularly extremities, and supported by innovations like ARVIS and Nebula. Despite macroeconomic volatility and tariff impacts, the company reaffirmed its full-year 2026 guidance, emphasizing continued execution and investment in its innovation pipeline. Adjusted gross margin improved to 62%, and adjusted EPS grew 10% to $0.89, with free cash flow expected to improve over the year.
A Quick Look at Today's Ratings for Enovis Corp(ENOV.US), With a Forecast Between $36 to $40
This article provides a summary of recent analyst ratings for Enovis Corp (ENOV.US), indicating a forecast share price between $36 and $40. It offers a snapshot of current market sentiment towards the company's stock.
A Quick Look at Today's Ratings for Enovis Corp(ENOV.US), With a Forecast Between $36 to $40
This article provides a brief overview of recent analyst ratings for Enovis Corp (ENOV.US), indicating a consensus forecast price between $36 and $40. It highlights the general sentiment among analysts for the company's stock.
Enovis Corporation (NYSE:ENOV) Q1 2026 Earnings Call Transcript
Enovis Corporation reported strong Q1 2026 earnings, surpassing expectations with an EPS of $0.89 against an anticipated $0.82. The company achieved 6% organic revenue growth on a days-adjusted basis, driven by 8% growth in Recon and 3% in Prevention & Recovery. Key drivers included the successful launch and adoption of the Arvis augmented reality system in Recon and continued market share gains in both segments despite a dynamic macroeconomic environment.
Enovis Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group has maintained its Outperform rating for Enovis. This indicates a continued positive outlook from the analyst firm regarding the company's performance.
Enovis (ENOV) Q1 2026 Earnings Transcript
Enovis (ENOV) reported Q1 2026 sales of $589 million, up 5% on a reported basis, with organic revenue growth of 3% driven by strong performance in Recon, particularly in U.S. Recon (8% organic growth). The company reaffirmed its full-year 2026 guidance, expecting revenue to be split evenly between the first and second halves, despite headwinds from international market volatility, $4 million in tariffs, and geopolitical factors in the Middle East. Management highlighted the successful soft launch of Arvis and continued investment in Recon's growth, while also discussing an updated Adjusted EBITDA definition due to SEC discussions.
Enovis: Q1 Earnings Snapshot
Enovis Corporation reported a first-quarter loss of $8.8 million, or 15 cents per share, with adjusted earnings of 89 cents per share on revenue of $589.2 million. The company provided full-year guidance, expecting earnings between $3.52 and $3.73 per share and revenue between $2.31 billion and $2.37 billion.
Enovis (ENOV) Quarter Shows Sharply Narrowed Loss Challenging Longstanding Bearish Narratives
Enovis (ENOV) reported Q1 2026 revenue of US$589.2 million and a significantly narrowed basic EPS loss of US$0.15, contrasting with larger losses in previous quarters. This challenges bearish narratives focusing on widening losses, as the company shows substantial progress towards profitability. Analysts forecast 126.52% annual earnings growth and a path to profitability within three years, with the current stock price trading well below its DCF fair value.
Enovis Q1 2026 Deep Dive: EPS Beats by 7.2%, Revenue Up 5%
Enovis Corporation reported a solid Q1 2026 earnings beat, with adjusted EPS exceeding estimates by 7.2% at $0.89 and revenue growing 5% year-over-year to $589.2M, primarily driven by its Reconstructive segment. Despite the adjusted EPS beat, the company experienced a GAAP net loss of $8.4M and negative net margin, alongside light operating cash flow, suggesting the beat was largely due to adjustments rather than fundamental operating improvements. Investors reacted moderately positively, valuing the maintained full-year guidance and Reconstructive segment strength over the profitability concerns.
Enovis Q1 2026 Deep Dive: EPS Beats by 7.2%, Revenue Up 5%
Enovis Corporation (ENOV) reported a strong Q1 2026 earnings beat with adjusted EPS exceeding estimates by 7.2% and revenue up 5.0% year-over-year, primarily driven by its Reconstructive segment. Despite the positive headline figures, underlying profitability metrics showed deterioration, with a net loss and low operating margin. The company maintained its full-year guidance, expressing confidence despite ongoing tariff headwinds, but operating cash flow generation remains a concern.
Why Is Enovis (ENOV) Stock Rocketing Higher Today
Shares of Enovis Corporation (ENOV) jumped 7.6% after the company reported better-than-expected first-quarter 2026 results, with revenue surpassing analyst estimates by 3.1% and adjusted EPS coming in 9.9% higher than consensus. The medical technology company also reaffirmed its strong full-year financial guidance. This positive performance has led to a significant market reaction, although the stock remains below its 52-week high.
Enovis (NYSE:ENOV) Exceeds Q1 CY2026 Expectations
Enovis (NYSE:ENOV) reported better-than-expected Q1 CY2026 results, with revenue up 5.4% year-on-year to $589.2 million and non-GAAP profit of $0.89 per share, beating analyst estimates by 9.9%. The company reconfirmed its full-year revenue and adjusted EPS guidance, indicating solid execution despite past weak revenue growth. While revenue growth has accelerated recently, analysts anticipate a deceleration in the next 12 months.
Press Release: Enovis Announces First Quarter 2026 Results
This is a press release from Enovis announcing its financial results for the first quarter of 2026. The full content of the press release is not provided in the input, but the title indicates a focus on the company's financial performance.
Earnings Flash (ENOV) Enovis Corporation Posts Q1 Adjusted EPS $0.89 per Share, vs. FactSet Est of $0.81
Enovis Corporation (ENOV) announced Q1 adjusted EPS of $0.89 per share, surpassing the FactSet estimate of $0.81. The article provides a company overview, financial details, analyst consensus, and recent news related to Enovis Corporation. Enovis specializes in medical technology, focusing on reconstructive surgery, rehabilitation, and pain management through its Prevention & Recovery and Reconstructive segments.
Enovis: Q1 Earnings Snapshot
Enovis Corporation (ENOV) reported a first-quarter loss of $8.8 million, or 15 cents per share. Despite the loss, adjusted earnings were 89 cents per share on revenue of $589.2 million. The company forecasts full-year earnings between $3.52 and $3.73 per share, with revenue projected to be between $2.31 billion and $2.37 billion.
Enovis (NYSE:ENOV) Exceeds Q1 CY2026 Expectations
Enovis (NYSE:ENOV) reported better-than-expected Q1 CY2026 results, with revenue up 5.4% year-on-year to $589.2 million and non-GAAP profit exceeding analyst estimates by 9.9%. The company reconfirmed its full-year revenue and adjusted EPS guidance, with management noting solid execution and continued progress in their innovation-led strategy. Despite weak long-term sales, recent growth trends suggest some improvements.
Stronger margins at Enovis (NYSE: ENOV) as Q1 2026 loss shrinks sharply
Enovis (NYSE: ENOV) reported a significantly narrowed net loss in Q1 2026, reaching $8.5 million compared to $55.7 million a year prior, driven by higher net sales of $589.2 million and improved gross margins. The company's gross profit margin expanded to 62.0%, and Adjusted EBITDA increased to $103.6 million, reflecting a better product mix, lower inventory step-up charges, and a favorable foreign currency translation. This improved financial performance, particularly in the Reconstructive segment, led to positive operating cash flow of $24.0 million, though the company remains leveraged with $1.33 billion in total debt.
Enovis (NYSE: ENOV) Q1 2026 sales rise 5%, margins expand and outlook held
Enovis (NYSE: ENOV) reported a strong first quarter for 2026, with net sales increasing by 5.4% year-over-year to $589.2 million, driven by significant growth in its Reconstructive segment. While the company posted a GAAP net loss of $8.5 million, adjusted net income and EBITDA saw substantial improvements, with adjusted EPS rising to $0.89. Enovis reaffirmed its full-year 2026 financial guidance, anticipating strong revenue, adjusted EBITDA, and EPS, indicating confidence in its operational strategy and market position despite macro uncertainties.
Earnings Flash (ENOV) Enovis Corporation Reports Q1 Revenue $589.2M, vs. FactSet Est of $572.0M
Enovis Corporation (ENOV) reported its Q1 revenue at $589.2 million, significantly exceeding FactSet's estimated $572.0 million. This financial beat indicates a stronger-than-anticipated performance for the medical technology company during the first quarter. The company specializes in developing and distributing medical devices for reconstructive surgery, rehabilitation, pain management, and physical therapy, operating through its Prevention & Recovery and Reconstructive segments.
Enovis: Q1 Earnings Snapshot
Enovis Corporation (ENOV) reported a loss of $8.8 million in its first quarter, amounting to 15 cents per share. Adjusted earnings were 89 cents per share, with the company posting revenue of $589.2 million. Enovis anticipates full-year earnings between $3.52 and $3.73 per share and revenue ranging from $2.31 billion to $2.37 billion.
Enovis Corporation Q1 2026 earnings preview
This article is a placeholder for the Q1 2026 earnings preview of Enovis Corporation. As no content was provided, a detailed summary is not possible.
Enovis (ENOV) Q1 Earnings Report Preview: What To Look For
Enovis Corporation (ENOV) is set to report its Q1 earnings this Thursday, with analysts expecting a 2.2% year-on-year revenue growth. The company missed revenue expectations last quarter but beat full-year EPS guidance. Investors are showing positive sentiment in the medical devices & supplies segment, and Enovis's stock is up 6.2% over the last month.
William Blair’s Focus on Cash Conversion Might Change The Case For Investing In Enovis (ENOV)
William Blair initiated coverage on Enovis Corporation (ENOV) with an Outperform rating, highlighting the importance of improved free cash flow conversion. The firm supports Enovis's conservative 2026 growth outlook and management's goal to increase free cash flow conversion from approximately 10% in 2025 to 25% in 2026, shifting investor focus from headline growth to cash generation. This new emphasis on free cash flow conversion is seen as a primary valuation driver, aligning with management's targets, though execution risks from acquisitions and technology rollouts remain.
William Blair’s Focus on Cash Conversion Might Change The Case For Investing In Enovis (ENOV)
William Blair initiated coverage on Enovis (ENOV) with an Outperform rating, highlighting the importance of free cash flow conversion for valuation. The firm supports Enovis' goal to increase cash flow conversion from approximately 10% in 2025 to 25% in 2026, shifting investor focus from headline growth to cash generation. This renewed emphasis by William Blair and a new stake from Vanguard underscore the need for Enovis to convert its revenue base into recurring free cash flow, despite inherent execution risks from acquisitions and technology rollouts.
|Enovis (NYSE:ENOV) Downgraded by Wall Street Zen to "Hold"
Wall Street Zen has downgraded Enovis (NYSE:ENOV) from a "buy" to a "hold" rating, despite the consensus analyst rating remaining a "Buy" with a target price of $47.43. The company reported strong Q1 EPS, beating estimates, but revenue slightly missed, and it has provided FY2026 EPS guidance between $3.520 and $3.730. Insider transactions show recent share purchases, and institutional investors have significantly increased their stakes in the company.
William Blair Initiates Enovis Corporation Coverage with Outperform Rating
William Blair has initiated coverage on Enovis Corporation (NYSE:ENOV) with an Outperform rating, noting significant valuation opportunities after a two-year stock price decline. The medical technology firm is trading at a P/E ratio of 9 times trailing earnings, considerably below the industry average of 15.5 times. Analysts believe the company's ability to generate liquidity and its revised growth outlook for 2026 (4-6% growth, 25% free cash flow conversion) make it an attractive investment, despite current market skepticism.
Enovis (ENOV) to Release Earnings on Thursday
Enovis (NYSE: ENOV) is scheduled to release its Q1 2026 earnings before the market opens on Thursday, May 7th. Analysts anticipate an EPS of $0.82 and revenue of approximately $573.0 million for the quarter. The company previously reported $0.95 EPS for the last quarter, surpassing estimates, and has a consensus "Buy" rating from analysts with an average price target of $47.43.
William Blair Assigns Outperform Rating to Enovis (ENOV)
William Blair initiated coverage on Enovis Corporation (ENOV) with an Outperform rating, citing valuation opportunities after a two-year stock drop. The research firm noted ENOV's attractive price-to-earnings ratio compared to peers and anticipates improved free cash flow conversion by 2026. Despite skepticism from investors, William Blair supports management's more conservative growth outlook for the company.
William Blair Assigns Outperform Rating to Enovis (ENOV)
William Blair has assigned an Outperform rating to Enovis (ENOV), highlighting valuation opportunities after a two-year stock drop. The research firm noted that Enovis is trading at a significantly lower price-to-earnings ratio compared to its peers and anticipates an improvement in free cash flow conversion by 2026. This positive outlook is supported by reduced cash charges and a more conservative growth forecast from the company's management.
Vanguard reports 5.23% stake in Enovis | ENOV SEC Filing - Form SCHEDULE 13G
Vanguard Capital Management has reported a 5.23% beneficial ownership stake in Enovis (ENOV) through a Schedule 13G filing. This amounts to 2,995,321 shares, with Vanguard exercising sole dispositive power over all these shares and sole voting power over 442,970 shares. The filing, signed by Vanguard's Head of Global Fund Administration, emphasizes transparency in securities ownership for public companies.
